30 March 2017 - Akari Therapeutics announced today that the US FDA has granted fast track designation for Coversin for treatment of paroxysmal nocturnal haemoglobinuria (PNH) in patients who have polymorphisms conferring eculizumab resistance.

Coversin is a second-generation complement inhibitor that acts on complement component-C5, preventing the release of C5a and the formation of C5b–9 (also known as the membrane attack complex or MAC), and independently also inhibits LTB4 activity.

Read Akari Therapeutics press release